We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.25 | -2.45% | 9.95 | 9.50 | 10.40 | 1,065,155 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -7.18 | 59.55M |
From Apr 2019 to Apr 2024
TIDMETX
RNS Number : 8523J
e-Therapeutics plc
04 April 2018
e-therapeutics plc
Notice of Annual General Meeting and Annual Report
4 April 2018: e-therapeutics plc (AIM: ETX, "e-therapeutics" or the "Company"), the drug discovery company, announces that its Annual Report and accounts for the year ended 31 January 2018, which includes the notice convening the Company's 2018 Annual General Meeting ("AGM"), can be downloaded from the Company's website at https://www.etherapeutics.co.uk/investors/reports-results/ and will be posted to Shareholders on 6 April 2018.
The 2018 AGM will take place at 11:00 am on 31 May 2018 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.
-Ends-
For more information, please contact:
e-therapeutics plc Tel: +44 (0)1993 Iain Ross, Chairman 883 125 Ray Barlow, Chief Executive www.etherapeutics.co.uk Officer Steve Medlicott, Finance Director Numis Securities Limited Tel: +44 (0) 207 Michael Meade / Freddie Barnfield 260 1000 (Nominated Adviser) www.numis.com James Black (Corporate Broking) Instinctif Partners Tel: +44 (0) 207 Melanie Toyne Sewell / Alex 457 2020 Shaw Email: e-therapeutics@instinctif.com
About e-therapeutics plc
e-therapeutics is an Oxford-based company with a unique and powerful computer-based drug discovery platform and specialised approach to network biology.
Its novel methodology and discovery engine allow the Company to discover new and better drugs in a more efficient and effective way.
For more information about the Company, please visit www.etherapeutics.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAUSAVRWUASRAR
(END) Dow Jones Newswires
April 04, 2018 11:13 ET (15:13 GMT)
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
